The study covers includes important players such as F. Hoffmann-La Roche, Heptares Therapeutics, Novo Nordisk AS, Omeros, Opiant Pharmaceuticals, Sunovion Pharmaceuticals etc
Request a sample report @ https://www.htfmarketreport.com/sample-report/1407017-binge-eating-disorder-pipeline-review-5
Binge Eating Disorder – Pipeline Review, H2 2018
HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder – Pipeline Review, H2 2018, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.
Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.
Report Highlights
HTF’s Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 6 respectively.
Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1407017
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System). – The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. – The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. – The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects. – The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. – The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/1407017-binge-eating-disorder-pipeline-review-5
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. – Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. – Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System). – Classify potential new clients or partners in the target demographic. – Develop tactical initiatives by understanding the focus areas of leading companies. – Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. – Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics. – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. – Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report: Chronos Therapeutics Ltd F. Hoffmann-La Roche Ltd Heptares Therapeutics Ltd Novo Nordisk AS Omeros Corp Opiant Pharmaceuticals Inc Sunovion Pharmaceuticals Inc
List of Tables Number of Products under Development for Binge Eating Disorder, H2 2018 Number of Products under Development by Companies, H2 2018 Products under Development by Companies, H2 2018 Number of Products by Stage and Target, H2 2018 Number of Products by Stage and Mechanism of Action, H2 2018 Number of Produc
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1407017-binge-eating-disorder-pipeline-review-5
Media ContactCompany Name: HTF Market Intelligence Consulting Private LimitedContact Person: Craig FrancisEmail: Send EmailPhone: 2063171218Address:Unit No. 429, Parsonage Road City: EdisonState: New JerseyCountry: United StatesWebsite: www.htfmarketreport.com/reports/1407017-binge-eating-disorder-pipeline-review-5
